AI in Drug Discovery Market Size, Share, Trends and Forecast, 2026-2034
REPORT DETAILS
AI in Drug Discovery Market Summary
The AI in drug discovery market size was valued at USD 2.29 billion in 2025. The market is projected to grow from USD 2.85 billion in 2026 to USD 16.77 billion by 2034, exhibiting a CAGR of 24.78% during 2026–2034.
Market Statistics
Key Takeaways
• North America held the largest market share of 38.0% in 2025. The presence of leading pharmaceutical and biotechnology companies contributed to the dominance. Also, the rising burden of chronic diseases drives the regional market growth.
• The U.S. led the North America market with 88.0% share in 2025. The U.S. comprises a world-leading research ecosystem. The country has the presence of top-tier universities, research institutions, and biotech startups. Such infrastructure is contributing to the U.S. market growth.
• The Asia Pacific AI in drug discovery market is expected to exhibit the highest CAGR of 27.40% during 2026–2034. This is due to the rapid development of healthcare infrastructure in the region.
• In 2025, the oncology segment held the largest market share of 29.0%. The dominance is attributed to the increasing prevalence of cancer across the world.
• The pharmaceutical & biotechnology companies segment is expected to register the highest CAGR of 25.60% during the forecast period. This is driven by rising R&D investments and surging emphasis on research and development in novel drug discovery.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Increasing pressure to reduce drug discovery timelines and R&D costs propels the adoption of AI platforms for target identification, molecule screening, and lead optimization.
- Rising availability of biomedical datasets, genomics data, and cloud computing infrastructure is enabling more accurate AI-driven drug discovery workflows.
- Data quality issues, fragmented healthcare datasets, and limited model interpretability hinder the full-scale deployment of AI in drug discovery.
- Growing use of generative AI (GenAI) and predictive modeling in novel molecule design would create strong growth opportunities for next-generation drug discovery platforms.
- Pharmaceutical companies, biotech firms, and AI technology providers are announcing strategic collaborations. It is expected to emerge as a key trend to accelerate pipeline development.
AI in Drug Discovery in Simple Terms
AI in drug discovery uses artificial intelligence (AI) and machine learning (ML). Scientists employ AI and ML to speed up the process of identifying and developing drugs. These technologies involve the analysis of vast amounts of biological and medical data. They allow researchers to find drug candidates and make predictions about their efficacy. Drug discovery through AI enhances the efficiency of drug development.
The AI in drug discovery market involves the application of artificial intelligence (AI) technologies at different stages of the drug discovery and development process. It encompasses the use of AI-driven tools and platforms to analyze biological data, identify potential drug candidates, predict their efficacy and safety, optimize drug design, and streamline clinical trials. The rising prevalence of chronic diseases like cancer, diabetes, cardiovascular diseases, and neurological disorders drives the market revenue. For instance, according to the American Diabetes Association, in 2021, the prevalence of diabetes in the United States was 11.6%, affecting 38.4 million Americans. This has led to an increasing demand for innovative and more potent drugs, thus driving demand for AI in drug discovery. Furthermore, the growing need for personalized medicine needs tools to analyze vast amounts of genetic and molecular data to develop targeted therapies. Consequently, the escalating demand for more potent drugs within shorter time frames is anticipated to propel the AI in drug discovery market growth during the forecast period.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
Traditional vs AI-Based Drug Discovery
| Comparison Factor | Traditional Drug Discovery | AI-Based Drug Discovery |
| Discovery Process | Relies on manual research, laboratory experiments, and iterative testing. | AI algorithms automate data analysis, target identification, and molecule discovery. |
| Development Speed | Long drug development cycles. They often take several years. | Significantly accelerates discovery by rapidly analyzing large datasets and predicting outcomes. |
| Drug Candidate Screening | Limited number of compounds can be tested through laboratory methods. | Screens millions of compounds virtually in a fraction of the time. |
| Cost Efficiency | High R&D costs due to extensive experimentation and higher failure rates. | Optimizes candidate selection and minimizes failed experiments. It reduces research costs. |
| Data Analysis | Primarily dependent on human interpretation and conventional statistical methods. | Processes complex genomic, biological, and clinical datasets using ML and predictive analytics. |
| Target Identification | Time-consuming identification of disease targets through laboratory research. | Rapidly identifies potential drug targets using AI-driven pattern recognition and biological modeling. |
| Prediction Accuracy | Greater reliance on trial-and-error approaches during early research stages. | Predicts drug efficacy, toxicity, and molecular interactions before laboratory validation. |
| Personalized Medicine | Limited ability to develop patient-specific therapies. | Supports precision medicine by analyzing patient genomic and clinical data for customized treatments. |
| Overall Efficiency | Slower, resource-intensive, and highly dependent on manual workflows. | Faster, more scalable, and highly efficient through automation and advanced predictive modeling. |
Source: Polaris Market Research Analysis
How AI in Drug Discovery Works
- The AI platform uses databases on biology and chemistry. This aids in the identification of patterns, connections, and other information about diseases through scientific data.
- Machine learning (ML) techniques identify drug targets and molecular patterns. It may assist in the discovery of new medicines.
- The predictive modeling technique tests the safety, effectiveness, and adverse reactions of medicines before laboratory testing.
- The virtual screening technology enables the analysis of millions of chemicals rapidly and the identification of the best candidates.
- The AI platform is employed in enhancing the design of clinical trials and selecting the appropriate participants.
- Scientists undertake laboratory studies, clinical trials, and other tasks for the commercialization of medicines.
Governments and private sectors are heavily investing in AI technologies for healthcare, including drug discovery. These investments are driving research and development efforts, fostering innovation, and encouraging the adoption of AI in drug discovery, significantly boosting market growth. Furthermore, the emergence of new diseases and global health crises, such as the COVID-19 pandemic, has highlighted the need for rapid drug discovery and development. The urgency to address these health challenges has led to increased funding and collaboration with the AI in the drug discovery market.
What is the Role of Generative AI in Drug Discovery?
AI-powered drug discovery is transforming itself using Generative AI (Gen AI). The technology can create new chemical structures and make predictions about the interaction between drugs and targets. It can come up with potential drugs much faster. Using advanced deep learning techniques, it comes up with drug candidates based on their biological properties. The use of Gen AI reduces the need for experimentations through trial-and-error method. It helps in the process of optimizing leads and assists in the screening of potential candidates. This results in decreased costs and time taken in drug discovery.
Real-World Applications of AI in Drug Discovery
| Application | How AI Helps |
| Cancer Drug Discovery & Precision Oncology | AI identifies drug targets, predicts treatment responses, and supports the development of targeted cancer therapies. |
| Rare Disease Treatment Development | The technology analyzes genetic and clinical data to accelerate the discovery of therapies for rare and underserved diseases. |
| Vaccine Research & Infectious Disease Therapies | AI speeds vaccine development by identifying promising antigens, predicting immune responses, and discovering potential antiviral treatments. |
| Drug Repurposing | AI evaluates existing medicines to identify new therapeutic applications, reducing development time, cost, and clinical risk. |
| Personalized Medicine Development | AI analyzes patient-specific genomic and clinical data to recommend customized treatment strategies and improve therapeutic outcomes. |
| Biomarker Identification & Genomic Analysis | AI detects disease biomarkers and interprets genomic data to enhance diagnosis, patient stratification, and precision drug development. |
Source: Polaris Market Research Analysis
AI in Drug Discovery Market Drivers and Trends
Collaboration Between Pharma Companies and AI Providers Drives Market Growth
Pharmaceutical companies are increasingly partnering with AI technology providers to enhance their drug discovery efforts. These collaborations combine the domain expertise of pharma companies with the computational power of AI, leading to more efficient drug development processes and innovative drug candidates. For instance, in May 2024, Sanofi, Formation Bio, and OpenAI announced collaboration to develop AI-powered software to speed up drug development and deliver new medicines to patients more efficiently. They will leverage data, software, and tuned models to create customized solutions across the drug development lifecycle. As a result, the market share of AI in drug discovery is anticipated to experience substantial growth during the forecast period.
Advancements in AI Technology Boost Market Growth
The continuous advancements in AI, particularly in natural language processing (NLP), predictive analytics, and quantum computing, are significantly expanding the capabilities of AI in drug discovery. These advancements are facilitating more precise predictions, improved drug-target interactions, and the identification of novel drug candidates. Furthermore, the integration of AI with genomics, proteomics, and other omics technologies is driving demand for personalized medicines. AI algorithms are adept at analyzing complex omics data to identify biomarkers and customize drug treatments based on individual genetic profiles. This personalized approach enhances the efficacy of therapies, thereby fueling the demand for AI in drug discovery solutions.
Rising Pharmaceutical R&D Costs and Pressure to Accelerate Drug Development
The high costs and increasing complexities involved in conducting research and development for pharmaceuticals have led to the increased use of AI in discovering drugs. Developing a drug involves a lot of testing and research and takes many years with high investments in the process. The technology is employed to cut down such costs. It helps in analyzing data and determining potential drug candidates. In addition, it reduces failure in experimentation within the early stages of research. AI models help in identifying targets and selecting the right leads, hence reducing time taken in development.
Market Challenges
- High Implementation and Infrastructure Costs: High investment is necessary in hardware, cloud services, software, and manpower for implementing artificial intelligence platforms. These high costs pose problems for small businesses.
- Privacy and Cyber Security Threats: Privacy of patient, genome and clinical trial data is important. There could be cybersecurity threats along with privacy challenges.
- Low-Quality Biological Data: High quality biological data is required by the machine learning model for its optimal functioning. Fragmented or biased biological data can affect the efficiency of the algorithm.
- Regulatory Challenges in AI-Based Drug Development: Regulatory framework for AI-based drug development is yet to evolve.
Source: Polaris Market Research Analysis
AI in Drug Discovery Market Segment Insights
AI in Drug Discovery Market Breakdown by Therapeutic Area Insights
The AI in drug discovery market segmentation, based on therapeutic area, includes oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious disease, and others. In 2024, the oncology segment accounted for the largest market share due to the rising prevalence of cancer patients worldwide. For instance, according to the CDC, the United States reported 1.77 million new cancer cases in 2021 and more than six lakh cancer-related deaths in 2022. This rise in cancer cases necessitates a faster drug development process in the oncology segment, resulting in increased adoption of AI in drug discovery and thereby driving the AI in drug discovery market growth.
AI in Drug Discovery Market Breakdown by End User Insights
The AI in drug discovery market segmentation, based on end user, includes, pharmaceutical & biotechnology companies, contract research organizations, research centers, academic & government institutes. The pharmaceutical & biotechnology companies’ category is expected to be the fastest-growing market segment due to increasing R&D investment. Pharmaceutical and biotechnology companies are significantly increasing their investments in research and development (R&D) to maintain a competitive edge and bring new drugs to market. AI technologies are being increasingly leveraged to optimize and accelerate the drug discovery process, enabling more efficient identification of potential drug candidates. For instance, Pfizer, a pharmaceutical company, has embraced Artificial Intelligence to streamline and accelerate clinical drug development. Thus, the growing need for research and development in novel drug discovery is expected to make the pharmaceutical and biotechnology companies segment the fastest-growing segment in the market during the forecast period.
Emerging Technology Trends in AI in Drug Discovery
| Technology Trend | Impact on Drug Discovery |
| Generative AI for Molecule Creation | Designs novel molecular structures with desired properties, accelerating lead identification and optimization. |
| Digital Twin Technologies in Drug Development | Creates virtual models of biological systems and patients to simulate drug responses and improve development outcomes. |
| AI-Powered Biomarker Discovery | Identifies disease biomarkers from genomic, proteomic, and clinical data to enable precision medicine and targeted therapies. |
| Quantum Computing in Pharmaceutical Research | Enhances molecular simulations and complex chemical calculations, supporting faster drug design and optimization. |
| Federated Learning for Healthcare Data Security | Enables AI model training across multiple institutions without sharing sensitive patient data, improving privacy and regulatory compliance. |
| Automated Robotic Laboratories Integrated with AI | Combines AI with laboratory automation to perform high-throughput experiments, accelerate compound screening, and improve research efficiency. |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
AI in Drug Discovery Market Breakdown by Regional Insights
By region, the study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The North America AI in drug discovery market accounted for the largest market share in 2024. North America, particularly the US, is home to many of the world's leading pharmaceutical and biotechnology companies. These companies have been early adopters of AI technologies to enhance their drug discovery processes, contributing to the market growth. Furthermore, the increasing prevalence of chronic diseases in North America is driving the demand for more efficient and personalized therapies. For example, the Centers for Disease Control and Prevention reports that nearly 116 million adults in the United States have hypertension. Consequently, the growing burden of chronic diseases necessitates a faster drug development process, which highlights the significant role of AI in drug development, thus contributing to the market growth in North America.
The US AI in drug discovery market had the largest market share in 2023. The US boasts a world-leading research ecosystem, with top-tier universities, research institutions, and biotech startups collaborating on AI in drug discovery. This ecosystem fosters innovation and rapid advancements, thereby contributing to the market growth in US.
The Asia Pacific AI in drug discovery market is expected to register the highest CAGR during the forecast period due to the rapid development of healthcare infrastructure in the region. Also, substantial investments in AI technologies by public and private entities is fueling market growth in the region. Furthermore, the increasing prevalence of chronic illnesses and the demand for personalized medicine are compelling pharmaceutical and biotechnology companies in the region to adopt AI-driven drug discovery processes. The sizable and diverse patient pool in countries such as China and India offers valuable data for AI models, significantly strengthening the region's potential for innovation in drug discovery. Additionally, government support and collaborations with global AI and healthcare companies are playing a crucial role in the rapid expansion of the market in the Asia Pacific region.
The Japan AI in drug discovery market is expected to grow significantly during the forecast period due to the country's strong emphasis on technological innovation and its advanced healthcare system. Japan's aging population and the associated increase in demand for novel therapies are driving demand for the adoption of AI in drug discovery. Additionally, Japan has a robust pharmaceutical industry that is increasingly investing in AI to accelerate drug development and reduce costs. The government's supportive policies, including funding for AI research and collaborations between academia, industry, and government institutions, further boost the growth of the AI in drug discovery market in Japan.
Source: Polaris Market Research Analysis
Regional Market Trends
| Region | Key Market Trend |
| North America | Market dominance will be supported by advanced biotechnology ecosystems, strong AI investments, leading pharmaceutical companies, and extensive research collaborations. |
| Europe | Strong pharmaceutical R&D capabilities, supportive regulatory initiatives, and increasing adoption of AI across drug discovery and precision medicine. |
| Asia-Pacific | Fastest-growing region due to expanding biotechnology industries, rising healthcare digitalization, government support, and increasing AI adoption in life sciences. |
| China & India | Rapid growth driven by expanding AI healthcare startups, strong pharmaceutical manufacturing capabilities, growing clinical research activities, and investments in biotech innovation. |
| Middle East & Latin America | Emerging markets with increasing investments in healthcare AI, biotechnology research, digital health infrastructure, and collaborations to strengthen pharmaceutical innovation. |
Source: Polaris Market Research Analysis
AI in Drug Discovery Market – Key Players and Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the AI in drug discovery market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, AI in drug discovery industry must offer cost-effective items.
In recent years, the AI in drug discovery industry has offered some technological advancements. Major players in the AI in drug discovery market include Atomwise Inc.; BenevolentAI; Berg Health (in January 2023, Berg Health acquired by BPGbio Inc.); BioSymetrics, Inc.; CYCLICA (Acquired by Recursion Pharmaceuticals); Exscientia; GNS Healthcare (In January 2023, the company Rebranded as Aitia); Google (DeepMind); IBM; Insilico Medicine; and insitro.
Recursion Pharmaceuticals, Inc. is a biotech company that uses advanced technology to decode biology and industrialize drug discovery. The company is developing multiple drugs in clinical trials, including treatments for cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, Clostridioides difficile infection, and AXIN1 or APC mutant cancers. Also, Recursion Pharmaceuticals, Inc. acquired Cyclica. In April 2023, Cyclica collaborated with Canadian platform to enhance the federated AI-driven insights in genomics and precision health.
International Business Machines Corporation (IBM) is an American multinational technology company operating in over 75 countries. It is the largest technology firm in the world and the second most valuable worldwide brand. The company mainly sells software which generates 29% of its revenue. Infrastructure services hold 37%, the hardware segment has 8%, and IT services hold 23%. The organization has an extensive network of 80,000 business associates who help it handle 5,200 clients, including 95% of the Fortune 500. Although IBM is a B2B firm, it has a significant external influence. The company is responsible for 50% of all wireless and 90% of all credit card transactions. In November 2023, IBM and Boehringer Ingelheim collaborated to further develop Generative AI and foundational models to enhance the process of therapeutic antibody development.
List of Key Companies in AI in Drug Discovery Market
- Atomwise Inc.
- BenevolentAI
- Berg Health (In January 2023, Berg Health acquired by BPGbio Inc.)
- BioSymetrics, Inc.
- CYCLICA (Acquired by Recursion Pharmaceuticals)
- Exscientia
- GNS Healthcare (In January 2023, the company Rebranded as Aitia)
- Google (DeepMind)
- IBM
- Insilico Medicine
- insitro
AI in Drug Discovery Industry Developments
- July 2026: Insilico Medicine and China Medical System Holdings Limited announced an AI‑empowered drug discovery collaboration. It is targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.(Source: PRNewswire)
Future Outlook
There will be high growth in the AI drug discovery market in the upcoming years. There has been an increasing number of applications of AI among pharmaceuticals and biotechnology companies for carrying out research and reducing costs in developing drugs. Machine learning, generative AI, and predictive analytics will play important roles in target identification and designing of molecules. Further advances will focus on personalized medicine, automation of the lab using AI, and integration of quantum computing for complex molecular simulations. Collaboration between technological vendors, research institutes, and pharmaceutical firms will be on the rise. Regulatory frameworks become mature and quality healthcare data becomes available. Thus, AI will play an increasingly important role in developing safer, faster, and more effective therapies worldwide.
AI in Drug Discovery Market Segmentation
By Offering Outlook
- Software
- Services
By Technology Outlook
- Machine Learning
- Deep Learning
- Supervised Learning
- Reinforcement Learning
- Unsupervised Learning
- Other Machine Learning Technologies
- Other Technologies
By Therapeutic Area Outlook
- Oncology
- Neurodegenerative Diseases
- Cardiovascular Disease
- Metabolic Diseases
- Infectious Disease
- Others
By Application Outlook
- Drug optimization & repurposing
- Preclinical testing
- Others
By End User Outlook
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Research Centers
- Academic & Government Institutes
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
AI in Drug Discovery Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 2.29 billion |
| Market Size Value in 2026 | USD 2.85 billion |
| Revenue Forecast in 2034 | USD 16.77 billion |
| CAGR | 24.78% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Frequently Asked Questions About the AI in Drug Discovery Market
The global AI in drug discovery market size was valued at USD 2.29 billion in 2025 and is projected to grow to USD 16.77 billion by 2034.
The global market is projected to grow at a CAGR of 24.78% during 2026–2034.
North America led with a 38.0% share in 2025
Key players in the market are Atomwise Inc.; BenevolentAI; Berg Health (in January 2023, Berg Health acquired by BPGbio Inc.); BioSymetrics, Inc.; CYCLICA (Acquired by Recursion Pharmaceuticals); Exscientia; GNS Healthcare (In January 2023, the company Rebranded as Aitia); Google (DeepMind); IBM; Insilico Medicine; and insitro.
The oncology segment dominated the market in 2025, accounting for a 29.0% share, driven by the rising prevalence of cancer worldwide.
The pharmaceutical & biotechnology companies’ category is expected to be the fastest-growing market segment due to increasing R&D investment
Artificial intelligence in drug discovery uses AI and ML technologies for discovering drug targets and designing molecules. The technologies help predict outcomes in the drug discovery process. Thus, AI speeds up drug development.
The technologies analyze biological, chemical, and clinical data. They aim to identify promising drug candidates and optimize the research process. They are used to predict toxicity and improve the efficiency of clinical trials.
Rising costs of pharmaceutical R&D, increasing need for precision medicine, and advances in machine learning technologies, drive the market growth. Also, growing availability of healthcare data and high investments in AI boost the growth.
AI-based drug discovery helps speed up the drug development process and facilitates target identification. It improves predictions and accelerates molecule screening. Personalized treatment development is also among the benefits.
In the future, there will be more implementation of generative AI, quantum computing, laboratory automation, personalized medicine, and clinical trials assisted by AI.
Download Sample Report of AI in Drug Discovery Market
Please fill out the form to request a customized copy of the research report.
